Trem2 Deficient Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TREM2-deficient microglia represent a critical state of microglial dysfunction that has emerged as a central mechanism in neurodegenerative diseases, particularly Alzheimer's disease. [1]
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions. [2]
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a transmembrane receptor primarily expressed on microglia in the central nervous system. Loss-of-function variants in TREM2 significantly increase the risk of developing Alzheimer's disease, with approximately 3-5-fold increased risk for heterozygous carriers of certain variants. [3]
TREM2 deficiency leads to reduced recruitment of microglia around amyloid plaques, resulting in: [4]
In tau pathology models, TREM2 deficiency results in: [5]
TREM2 plays a complex role in neuroinflammation:
Several TREM2-targeting therapies have entered clinical trials for Alzheimer's disease, focusing on:
The study of Trem2 Deficient Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
TREM2 deficiency leads to altered microglial function and neuronal damage. ↩︎
Microglial TREM2 deficiency exacerbates alpha-synuclein pathology in Parkinson's disease models. ↩︎
TREM2-targeted antibody therapeutics in clinical development for Alzheimer's disease. ↩︎
TREM2 variants and Alzheimer's disease risk: a meta-analysis. ↩︎